<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28178396</article-id><article-id pub-id-type="pmc">5406587</article-id><article-id pub-id-type="doi">10.1111/cas.13189</article-id><article-id pub-id-type="publisher-id">CAS13189</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Basic and Clinical Immunology</subject></subj-group></subj-group></article-categories><title-group><article-title>Immunological evaluation of peptide vaccination for cancer patients with the <styled-content style="fixed-case">HLA</styled-content> &#x02010;A11<sup>+</sup> or &#x02010;A33<sup>+</sup> allele</article-title><alt-title alt-title-type="left-running-head">Sakamoto <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="cas13189-cr-0001" contrib-type="author" corresp="yes"><name><surname>Sakamoto</surname><given-names>Shinjiro</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2805-900X</contrib-id><address><email>sakamoto_shinjiro@kurume-u.ac.jp</email></address><xref ref-type="aff" rid="cas13189-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="cas13189-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="cas13189-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cas13189-cr-0002" contrib-type="author"><name><surname>Matsueda</surname><given-names>Satoko</given-names></name><xref ref-type="aff" rid="cas13189-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas13189-cr-0003" contrib-type="author"><name><surname>Takamori</surname><given-names>Shinzo</given-names></name><xref ref-type="aff" rid="cas13189-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cas13189-cr-0004" contrib-type="author"><name><surname>Toh</surname><given-names>Uhi</given-names></name><xref ref-type="aff" rid="cas13189-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cas13189-cr-0005" contrib-type="author"><name><surname>Noguchi</surname><given-names>Masanori</given-names></name><xref ref-type="aff" rid="cas13189-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas13189-cr-0006" contrib-type="author"><name><surname>Yutani</surname><given-names>Shigeru</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6306-4130</contrib-id><xref ref-type="aff" rid="cas13189-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas13189-cr-0007" contrib-type="author"><name><surname>Yamada</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="cas13189-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas13189-cr-0008" contrib-type="author"><name><surname>Shichijo</surname><given-names>Shigeki</given-names></name><xref ref-type="aff" rid="cas13189-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas13189-cr-0009" contrib-type="author"><name><surname>Yamada</surname><given-names>Teppei</given-names></name><xref ref-type="aff" rid="cas13189-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="cas13189-cr-0010" contrib-type="author"><name><surname>Suekane</surname><given-names>Shigetaka</given-names></name><xref ref-type="aff" rid="cas13189-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="cas13189-cr-0011" contrib-type="author"><name><surname>Kawano</surname><given-names>Kouichiro</given-names></name><xref ref-type="aff" rid="cas13189-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="cas13189-cr-0012" contrib-type="author"><name><surname>Naitou</surname><given-names>Masayasu</given-names></name><xref ref-type="aff" rid="cas13189-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas13189-cr-0013" contrib-type="author"><name><surname>Sasada</surname><given-names>Tetsuro</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2313-8833</contrib-id><xref ref-type="aff" rid="cas13189-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="cas13189-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="cas13189-cr-0014" contrib-type="author"><name><surname>Hattori</surname><given-names>Noboru</given-names></name><xref ref-type="aff" rid="cas13189-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cas13189-cr-0015" contrib-type="author"><name><surname>Kohno</surname><given-names>Nobuoki</given-names></name><xref ref-type="aff" rid="cas13189-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="cas13189-cr-0016" contrib-type="author"><name><surname>Itoh</surname><given-names>Kyogo</given-names></name><xref ref-type="aff" rid="cas13189-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="cas13189-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Research Center for Innovative Cancer Therapy</named-content><institution>Kurume University</institution><named-content content-type="city">Kurume</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Cancer Vaccine Center</named-content><institution>Kurume University</institution><named-content content-type="city">Kurume</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Molecular and Internal Medicine School of Medicine</named-content><named-content content-type="organisation-division">Graduate School of Biomedical and Health Sciences</named-content><institution>Hiroshima University</institution><named-content content-type="city">Hiroshima</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Surgery</named-content><institution>Kurume University School of Medicine</institution><named-content content-type="city">Kurume</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Gastroenterological Surgery</named-content><institution>Fukuoka University School of Medicine</institution><named-content content-type="city">Fukuoka</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Urology</named-content><institution>Kurume University School of Medicine</institution><named-content content-type="city">Kurume</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Department of Obstetrics and Gynecology</named-content><institution>Kurume University School of Medicine</institution><named-content content-type="city">Kurume</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0008"><label><sup>8</sup></label><institution>Kanagawa Cancer Center Research Institute</institution><named-content content-type="city">Yokohama</named-content><country country="JP">Japan</country></aff><aff id="cas13189-aff-0009"><label><sup>9</sup></label><institution>Hiroshima Cosmopolitan University</institution><named-content content-type="city">Hiroshima</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Shinjiro Sakamoto, MD, Research Center for Innovative Cancer Therapy, Kurume University, 67 Asahi&#x02010;machi, Kurume 830&#x02010;0011, Japan. Tel: +81&#x02010;942&#x02010;31&#x02010;7989; E&#x02010;mail: <email>sakamoto_shinjiro@kurume-u.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><volume>108</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/cas.2017.108.issue-4</issue-id><fpage>598</fpage><lpage>603</lpage><history><date date-type="received"><day>17</day><month>10</month><year>2016</year></date><date date-type="rev-recd"><day>25</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Japanese Cancer Association <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Cancer Science published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Cancer Association</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-108-598.pdf"/><abstract id="cas13189-abs-0001"><p>The <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11 or &#x02010;A33 allele is found in approximately 18% or 10% of the Asian population, respectively, but each of which is a minor allele worldwide, and therefore no clinical trials were previously conducted. To develop a therapeutic peptide vaccine for each of them, we investigated immunological responses of advanced cancer patients with the <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11<sup>+</sup>/A11<sup>+</sup> (<italic>n&#x000a0;=&#x000a0;</italic>18) or &#x02010;A33<sup>+</sup>/A33<sup>+</sup> (<italic>n&#x000a0;=&#x000a0;</italic>13) allele to personalized peptide vaccine (<styled-content style="fixed-case">PPV</styled-content>) regimens. The primary sites of <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11+/A11+ or &#x02010;A33+/A33+ patients were the colon (<italic>n&#x000a0;=&#x000a0;</italic>4 or 2), stomach (2 or 3), breast (3 or 2), lung and pancreas (2 or 2), and so on. For <styled-content style="fixed-case">PPV</styled-content>, a maximum of four peptides were selected from nine different peptides capable of binding to <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11 and &#x02010;A33 molecules based on the pre&#x02010;existing peptide&#x02010;specific IgG responses. There were no severe adverse events related to <styled-content style="fixed-case">PPV</styled-content>. At the end of the first cycle, peptide&#x02010;specific <styled-content style="fixed-case">CTL</styled-content> responses were augmented in 4/12 or 2/9 of <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11<sup>+</sup>/A11<sup>+</sup> or &#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients, while peptide&#x02010;specific IgG responses were augmented in 6/14 or 4/10 patients, respectively. Clinical responses consisted of four stable diseases and 14 progressive diseases in <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11<sup>+</sup>/A11<sup>+</sup>patients, versus seven and six in &#x02010;A33<sup>+</sup>/A33<sup>+</sup>patients, respectively. Further clinical study of <styled-content style="fixed-case">PPV</styled-content> could be recommended because of the safety and positive immunological responses.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cas13189-kwd-0001">cytotoxic T&#x02010;Lymphocytes</kwd><kwd id="cas13189-kwd-0002"><styled-content style="fixed-case">HLA</styled-content>&#x02010;A11</kwd><kwd id="cas13189-kwd-0003"><styled-content style="fixed-case">HLA</styled-content>&#x02010;A33</kwd><kwd id="cas13189-kwd-0004">IgG</kwd><kwd id="cas13189-kwd-0005">peptide vaccine</kwd></kwd-group><funding-group><award-group><funding-source>Japan Agency for Medical Research and development</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="6"/><word-count count="5173"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cas13189</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:27.04.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cas13189-cit-1001">
<source>Cancer Sci</source>
<volume>108</volume> (<year>2017</year>) <fpage>598</fpage>&#x02013;<lpage>603</lpage>
</mixed-citation>
</p></notes><notes><fn-group id="cas13189-ntgp-0001"><fn id="cas13189-note-1001"><p>
<bold>Funding Information</bold>
</p><p>Japan Agency for Medical Research and Development, Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan</p></fn><fn id="cas13189-note-1002"><p>Clinical Trial Number: UMIN Clinical Trials Registry UMIN no. 1482, 1844, 1856, 1883, 2282, 2908, 2984, 2987, 3028, 3081, 6249, 6295, 6493, 7493, 10290 and 11230</p></fn></fn-group></notes></front><body><p>Although many clinical trials of peptide&#x02010;based cancer vaccines for HLA&#x02010;A2<sup>+</sup> and &#x02010;A24<sup>+</sup> cancer patients have been conducted in the past two decades, cancer patients with the other alleles, including the HLA&#x02010;A11 and &#x02010;A33 allele, were excluded from the clinical trials because of the relatively lower expression of these alleles worldwide.<xref rid="cas13189-bib-0001" ref-type="ref">1</xref>, <xref rid="cas13189-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref>, <xref rid="cas13189-bib-0007" ref-type="ref">7</xref>, <xref rid="cas13189-bib-0008" ref-type="ref">8</xref> We identified short peptides capable of inducing CTLs in HLA&#x02010;A11<sup>+</sup> or &#x02010;A33<sup>+</sup> cancer patients.<xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref> Some of them were provided for clinical trials to advanced cancer patients refractory or intolerant to standard therapy under PPV regimens in the past 7&#x000a0;years. The HLA&#x02010;A11 or &#x02010;A33 allele is found in approximately 18.2% or 9.9% of the Asian population (10.4% or 7.7% in the Japanese, 9.4% or 14.9% in the Korean, 20.3% or 3.4% in the North Han, and 32.5% or 13.6% in the Thai population), 5.9% or 2.2% of the European population (5.5% and 1.0% in the US Caucasian, 6.2% or 3.1% in the French, 4.6% or 3.1% in the German, and 7.3% or 1.7% in the British population), 7.9% or 3.9% of the Spanish population (7.0% or 2.8% in the Spanish, and 8.8% or 5.0% in the Gypsy population), and 1.1% and 8.7% of the Black population (4.2% or 8.0% in the North African, 0.0% or 1.5% in the South African, 0.0 or 15.2 of the West Africa, and 0.0 or 10.0% in the Senegalese population), respectively.<xref rid="cas13189-bib-0007" ref-type="ref">7</xref>, <xref rid="cas13189-bib-0008" ref-type="ref">8</xref> To develop peptide&#x02010;based cancer vaccines for cancer patients in these minor populations, we conducted clinical studies of PPV for advanced cancer patients with the HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> or &#x02010;A33<sup>+</sup>/A33<sup>+</sup> allele in the past 7&#x000a0;years, and report herein the safety and immune responses of these clinical trials. Although we also performed the same PPV regimes for HLA&#x02010;A11 or &#x02010;A33 cancer patients who co&#x02010;expressed the other HLA&#x02010;A, including the &#x02013;A2, &#x02010;A24, or &#x02010;A3 supertype, or &#x02013;A26, those results were not included in this retrospective study.</p><sec id="cas13189-sec-0002"><title>Patients and Methods</title><sec id="cas13189-sec-0003"><title>Peptides</title><p>Nine different CTL epitope peptides&#x02014;CypB <sub>129&#x02013;138</sub> KLKHYGPGWV, Lck <sub>90&#x02013;99</sub> ILEQSGEWWK, Lck <sub>422&#x02013;430</sub> DVWSFGILL, Lck <sub>449&#x02013;458</sub> VIQNLERGYR, WHSC2 <sub>103&#x02013;111</sub> ASLDSDPWV, SART3 <sub>109&#x02013;118</sub> VYDYNCHVDL, SART3 <sub>511&#x02013;519</sub> WLEYYNLER, SART3 <sub>734&#x02013;742</sub> QIRPIFSNR and PAP <sub>248&#x02013;257</sub> GIHKQKEKSR&#x02014;were used in this study. These peptides were previously shown to be capable of inducing peptide&#x02010;specific and tumor&#x02010;reactive CTL activity in HLA &#x02010;A11<sup>+</sup> and &#x02010;A33<sup>+</sup> cancer patients.<xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref> These peptides were prepared under the conditions of Good Manufacturing Practice by the PolyPeptide Laboratories (San Diego, CA, USA) and American Peptide Company (Vista, CA, USA) as reported previously.<xref rid="cas13189-bib-0001" ref-type="ref">1</xref>, <xref rid="cas13189-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref>
</p></sec><sec id="cas13189-sec-0004"><title>Patients</title><p>This is a retrospective analysis with cancer patients with HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> or &#x02010;A33<sup>+</sup>/A33<sup>+</sup>, who were enrolled in phase II studies of PPV with different regimens for different types of cancers. 18 HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients, including four colon, three breast, two pancreas, two lung, two prostate, two stomach, two biliary tract, and each of bone, uterus and ovary patients, and 13 HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients, including three stomach, two pancreas, two breast, two lung, two colon, and each of prostate and bone patients, were enrolled. They had to show positive IgG responses to at least two of the nine peptide candidates applicable for HLA&#x02010;A11<sup>+</sup>and &#x02010;A33<sup>+</sup> cancer patients.<xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref> Other inclusion criteria were as follows: age between 20 and 80&#x000a0;years; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of first visit; life expectancy of at least 12&#x000a0;weeks; and adequate hematologic, hepatic, and renal function. Exclusion criteria included pulmonary, cardiac, or other systemic diseases; an acute infection; a history of severe allergic reactions; pregnancy or nursing; and other inappropriate conditions for enrollment as judged by clinicians. These studies were approved by the Kurume University Ethical Committee and registered in the UMIN Clinical Trials Registry (UMIN no. 1482, 1844, 1856, 1883, 2282, 2908, 2984, 2987, 3028, 3081, 6249, 6295, 6493, 7493, 10290 and 11230). All patients were given a full explanation of the protocol and provided their informed consent before enrollment.</p></sec><sec id="cas13189-sec-0005"><title>Clinical protocol</title><p>The main objective of these phase II studies was to evaluate the safety and immunological responses. The secondary endpoints were clinical benefits from the viewpoint of overall survival (OS) and biomarker analysis. Peptides for vaccination to individual patients were selected in consideration of the pre&#x02010;existing host immunity before vaccination, as assessed by the titers of IgG specific to each of the nine different vaccine candidates.<xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref> A maximum of four peptides (3&#x000a0;mg/each peptide), which were selected based on the results of HLA typing and peptide&#x02010;specific IgG titers, were subcutaneously administered with incomplete Freund's adjuvant (Montanide ISA51; Seppic, Paris, France). There are three different administration interval regimens based on the different protocols for different sites of primary cancers (Fig.&#x000a0;<xref rid="cas13189-fig-0001" ref-type="fig">1</xref>). Administration interval of 1st cycle were six times weekly (UMIN no. 1482, 1844, 1856, 1883, 2282, 6249, 6295, 6493, 7493 and 10290), four times weekly followed by four times every 2&#x000a0;weeks (UMIN no. 2908, 2984, 2987, 3028 and 3081), or four times every 4&#x000a0;weeks (UMIN no. 11230), respectively. After the first cycle of vaccinations, up to four antigen peptides were re&#x02010;selected according to the titers of peptide&#x02010;specific IgG. Administration interval of 2nd cycle were six times every 2&#x000a0;weeks (UMIN no. 1482, 1844, 1856, 1883, 2282, 6249, 6295, 6493, 7493 and 10290), eight times every 2&#x000a0;weeks (UMIN no. 2908, 2984, 2987, 3028 and 3081), or four times every 4&#x000a0;weeks (UMIN no. 11230). During the PPV, patients were allowed to receive combination therapies, including chemotherapies such as target therapy, hormone therapy, or radiotherapy. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI&#x02010;CTC Ver.&#x02010;4.0). Complete blood counts and serum biochemistry tests were performed before and after each cycle of vaccinations. Tumor assessments by computed tomography (CT) or magnetic resonance imaging (MRI)&#x000a0;scans were carried out before and after PPV, and were evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.</p><fig fig-type="Figure" xml:lang="en" id="cas13189-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Personalized peptide vaccine's flow and three kinds of administration interval.</p></caption><graphic id="nlm-graphic-3" xlink:href="CAS-108-598-g001"/></fig></sec><sec id="cas13189-sec-0006"><title>Laboratory markers</title><p>Humoral immune responses specific to the vaccine peptides were determined by peptide&#x02010;specific IgG levels using a bead&#x02010;based multiplex assay with the Luminex system (Luminex, Austin, TX, USA) as previously reported.<xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref> If the titers of peptide&#x02010;specific IgG to at least one of the vaccinated peptides at the end of the 1st cycle were more than two&#x02010;fold higher than those in the pre&#x02010;vaccination plasma, the changes were considered to be significant as previously reported.<xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref> Cytotoxic T lymphocyte (CTL) responses specific to the vaccinated peptides were evaluated by capacity of interferon (IFN)&#x02010;&#x003b3; production with ELISPOT assays (MBL, Nagoya, Japan) using peripheral blood mononuclear cells (PBMCs) before and at the end of the first and second cycle as previously reported.<xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref>, <xref rid="cas13189-bib-0009" ref-type="ref">9</xref> As non&#x02010;vaccinated peptides, a mixture of virus&#x02010;derived CTL epitopes (CEF peptides; Mabtech) was provided for the assay. In the CTL assay, if the spot numbers in response to at least one of the vaccine peptides in the post&#x02010;vaccination PBMC were more than two&#x02010;fold higher than those in the pre&#x02010;vaccination PBMC, the changes were considered significant. Moreover, in order to evaluate the strength of the peptide&#x02010;specific IgG response, we evaluated the rate of changes of peptide&#x02010;specific IgG titers between before and after the first or second cycle of vaccination. In this evaluation, IgG titers before PPV were set to 1.0. We also assessed the significance of strength of the peptide&#x02010;specific IgG response after the second cycle of vaccination. Patients who finished the second cycle of PPV were divided into two subgroups according to the median value of the rate of changes of peptide&#x02010;specific IgG titers between before and after the second cycle of vaccination. Regarding the cytokines, the levels of granulocyte macrophage colony&#x02010;stimulating factor (GM&#x02010;CSF), interleukin (IL)1&#x003b2; IL2, IL4, IL5, IL6, IL8, IL10 and tumor necrosis factor (TNF)&#x02010;&#x003b1; in plasma before and after one cycle of vaccination were measured with a Luminex system (Luminex) using kits from Thermo Fisher Scientific K.K. (Yokohama, Japan), as reported previously.<xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0009" ref-type="ref">9</xref>
</p></sec><sec id="cas13189-sec-0007"><title>Statistical analyses</title><p>All data were analyzed retrospectively. Comparison of quantitative variables was carried out by Welch's <italic>t</italic>&#x02010;test or Mann&#x02013;Whitney <italic>U</italic>&#x02010;test. Comparison of categorical variables was carried out by the chi&#x02010;square test. The survival curves were estimated by the Kaplan&#x02013;Meier method, and differences in survival functions were compared using the log&#x02010;rank test. OS was calculated from the 1st day of peptide vaccination until the date of death or the last date when the patient was known to be alive using the log&#x02010;rank test. Values of <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 were considered statistically significant. Statistical analyses were conducted using JMP version software, version 12 (SAS Institute Inc., Cary, NC, USA).</p></sec></sec><sec id="cas13189-sec-0008"><title>Results</title><sec id="cas13189-sec-0009"><title>Patients&#x02019; characteristics</title><p>Between January 2009 and November 2015, 31 advanced cancer patients with HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> (<italic>n&#x000a0;=&#x000a0;</italic>18) or &#x02010;A33<sup>+</sup>/A33<sup>+</sup> (<italic>n&#x000a0;=&#x000a0;</italic>13) were enrolled in this study. Their genotypes were all HLA&#x02010;A11:01 or HLA&#x02010;A33:03, respectively. Details of the patients&#x02019; characteristics are shown in Table&#x000a0;<xref rid="cas13189-tbl-0001" ref-type="table-wrap">1</xref>. The median age of HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients was 59&#x000a0;years with 7 males and 11 females. Performance status was 0 in 13 and 1 in 15 patients. The sites of primary cancers were the colon (<italic>n&#x000a0;=&#x000a0;</italic>4), breast (3), pancreas (2), lung (2), prostate (2), stomach (2), biliary tract (2), and each of bone, uterus and ovary. All patients had failed (<italic>n&#x000a0;=&#x000a0;</italic>15) or proven intolerant to (<italic>n&#x000a0;=&#x000a0;</italic>3) standard chemotherapy before entry to PPV. Eleven patients received PPV combined with systemic therapies, whereas the remaining seven patients received PPV alone since of intolerance to any combined systemic therapies. The median vaccination time was 4.6&#x000a0;months (0.0&#x02013;29.0).</p><table-wrap id="cas13189-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients&#x02019; characteristics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup>
</th><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P</italic>&#x02010;value<xref ref-type="fn" rid="cas13189-note-0003">&#x02020;</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">(<italic>n&#x000a0;=&#x000a0;</italic>18)</th><th align="center" valign="top" rowspan="1" colspan="1">(<italic>n&#x000a0;=&#x000a0;</italic>13)</th><th valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age (range)</td><td align="char" char=" " rowspan="1" colspan="1">59 (20&#x02013;71)</td><td align="char" char=" " rowspan="1" colspan="1">58 (23&#x02013;84)</td><td align="char" char="." rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male/Female</td><td align="char" char="/" rowspan="1" colspan="1">7/11</td><td align="char" char="/" rowspan="1" colspan="1">9/4</td><td align="char" char="." rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" colspan="4" rowspan="1">Performance status</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0/1</td><td align="char" char="/" rowspan="1" colspan="1">13/15</td><td align="char" char="/" rowspan="1" colspan="1">10/3</td><td align="char" char="." rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" colspan="4" rowspan="1">Primary tumor site</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreas</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="11" colspan="1">0.35</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Breast</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Colon</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prostate</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stomach</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bone</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Liver</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Biliary tract</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Uterus</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oval</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage at diagnosis II/III/IV/Recurrence</td><td align="char" char="/" rowspan="1" colspan="1">0/1/7/10</td><td align="char" char="/" rowspan="1" colspan="1">2/1/6/4</td><td align="char" char="." rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Median lymphocyte count of enrollment</td><td align="char" char=" " rowspan="1" colspan="1">1372 (911&#x02013;2055)</td><td align="char" char=" " rowspan="1" colspan="1">1411 (1071&#x02013;2656)</td><td align="char" char="." rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" colspan="4" rowspan="1">Previous chemotherapy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">+/&#x02212;</td><td align="char" char="/" rowspan="1" colspan="1">3/15</td><td align="char" char="." rowspan="1" colspan="1">3/10</td><td align="char" char="." rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" colspan="4" rowspan="1">Combined chemotherapy with PPV</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">+/&#x02212;</td><td align="char" char="/" rowspan="1" colspan="1">7/11</td><td align="char" char="." rowspan="1" colspan="1">4/9</td><td align="char" char="." rowspan="1" colspan="1">0.72</td></tr></tbody></table><table-wrap-foot><fn id="cas13189-note-0003"><p>PPV, personalized peptide vaccine. &#x02020;Welch test or the &#x003c7;<sup>2</sup> test was performed to examine <italic>P</italic>&#x02010;values for continuous values or categorical values.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The median age of HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients was 58&#x000a0;years with nine males and four females. Performance status was 0 in 10 and 1 in three patients. The sites of primary cancers were the stomach (<italic>n&#x000a0;=&#x000a0;</italic>3), pancreas (2), breast (2), lung (2), colon (2), and each of prostate and bone. All patients failed (<italic>n&#x000a0;=&#x000a0;</italic>10) or proved intolerant to (<italic>n&#x000a0;=&#x000a0;</italic>3) standard chemotherapy before entry to PPV. Nine patients received PPV combined with systemic therapies, whereas the remaining four patients received PPV alone since of intolerance to any combined systemic therapies. The median vaccination time was 3.8&#x000a0;months (1.4&#x02013;31.9).</p></sec><sec id="cas13189-sec-0010"><title>Adverse events</title><p>Grade I (<italic>n&#x000a0;=&#x000a0;</italic>21) or II (<italic>n&#x000a0;=&#x000a0;</italic>6) injection site skin reactions were the most frequently observed adverse events during PPV (Table&#x000a0;<xref rid="cas13189-sup-0001" ref-type="supplementary-material">S1</xref>). There were 18 cases of grade 3 severe adverse events (SAEs), and one case of grade 4 SAE (leukopenia). All of the SAEs were concluded to be not directly associated with the PPV, but with the disease progression or combined therapy according to the evaluation by an independent safety evaluation committee.</p></sec><sec id="cas13189-sec-0011"><title>Immune responses</title><p>Both peptide&#x02010;specific CTL and IgG responses were analyzed in blood samples before and after the first or second cycle of vaccination. CTL responses to the vaccinated peptides before vaccination were detected in only 1 of 12 HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> or 0 of 9 HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients tested, respectively (Tables <xref rid="cas13189-sup-0002" ref-type="supplementary-material">S2</xref> and <xref rid="cas13189-sup-0003" ref-type="supplementary-material">S3</xref>). In contrast, those to the non&#x02010;vaccinated control CEF peptides were observed in nine of 12 or four of nine patients, respectively. CTL boosting in response to the vaccinated peptides at the end of the first cycle was observed in four of 12 HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> or two of nine HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients tested, and that at the end of the second cycle was observed in three of six or one of seven, respectively. In contrast, IFN&#x02010;&#x003b3; spots of CTL activity in response to the non&#x02010;vaccinated control CEF peptides were not significantly different throughout the PPV (Tables <xref rid="cas13189-sup-0002" ref-type="supplementary-material">S2</xref> and <xref rid="cas13189-sup-0003" ref-type="supplementary-material">S3</xref>).</p><p>IgG responses before vaccination were well observed in all patients. Increase of IgG responses specific to at least one of the vaccinated peptides after the 1st and 2nd cycles were observed in six of 14 and seven of seven patients tested with the HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup>, and in four of 10 and seven of nine patients tested with the &#x02010;A33<sup>+</sup>/A33<sup>+</sup> (Tables <xref rid="cas13189-sup-0002" ref-type="supplementary-material">S2</xref> and <xref rid="cas13189-sup-0003" ref-type="supplementary-material">S3</xref>). Regarding the rate of changes of peptide&#x02010;specific IgG titers, a 25&#x02010; or 127&#x02010;fold increase of IgG response was observed in the samples at the end of the first or second cycle when the titers of pre&#x02010;vaccinations were set as 1.0 in HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients (<italic>P&#x000a0;=&#x000a0;</italic>0.08 or <italic>P&#x000a0;=&#x000a0;</italic>0.002), respectively (Fig.&#x000a0;<xref rid="cas13189-fig-0002" ref-type="fig">2</xref>a). Similarly, a 4&#x02010; or 41&#x02010;fold increase of IgG response was observed in HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients (<italic>P&#x000a0;=&#x000a0;</italic>0.11 or <italic>P&#x000a0;=&#x000a0;</italic>0.01, respectively). Moreover, regarding the significance of strength of the peptide&#x02010;specific IgG response after 2nd cycle of vaccination, the patients with higher rate of changes of peptide&#x02010;specific IgG titers after 2nd cycle of vaccination showed longer prognosis than those with lower rate (<italic>P&#x000a0;=&#x000a0;</italic>0.03; Fig.&#x000a0;<xref rid="cas13189-fig-0002" ref-type="fig">2</xref>b).</p><fig fig-type="Figure" xml:lang="en" id="cas13189-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Immune responses. (a) Rates of changes of peptide&#x02010;specific IgG titers. A 25&#x02010; or 127&#x02010;fold increase of IgG titers was observed when the IgG titers of pre&#x02010;vaccinations were set as 1.0 in <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients (<italic>P&#x000a0;=&#x000a0;</italic>0.08 or <italic>P&#x000a0;=&#x000a0;</italic>0.002), respectively. Similarly, a 4&#x02010; or 41&#x02010;fold increase was observed in <styled-content style="fixed-case">HLA</styled-content>&#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients (<italic>P&#x000a0;=&#x000a0;</italic>0.11 or <italic>P&#x000a0;=&#x000a0;</italic>0.01). Fig.&#x000a0;<xref rid="cas13189-fig-0002" ref-type="fig">2</xref>(b): To examine the significance of strength of the peptide&#x02010;specific IgG response, when 16 <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11<sup>+</sup>/A11<sup>+</sup> or &#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients who finished 2nd cycle of <styled-content style="fixed-case">PPV</styled-content> were divided into two subgroups according to the median value of the rate of changes of peptide&#x02010;specific IgG titers between before and after 2nd cycle of vaccination, the patients with higher rate of changes of peptide&#x02010;specific IgG titers after 2nd cycle of vaccination showed longer prognosis than those with lower rate (<italic>P&#x000a0;=&#x000a0;</italic>0.03).</p></caption><graphic id="nlm-graphic-5" xlink:href="CAS-108-598-g002"/></fig></sec><sec id="cas13189-sec-0012"><title>Clinical response and biomarkers</title><p>Best clinical responses were evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 based on tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI)&#x000a0;scans before and after PPV. There were no complete or partial responses. There were four cases of stable disease and 14 of progressive disease in HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients with a median overall survival (MST) of 332&#x000a0;days, while these numbers were seven and six in &#x02010;A31<sup>+</sup>/A31<sup>+</sup> patients with an MST of 177&#x000a0;days, respectively. Most patients received PPV combined with chemotherapy, hormone therapy, or radiotherapy, and therefore it was difficult to evaluate the true contribution of the PPV to SD. However, one HLA&#x02010;A31<sup>+</sup>/A31<sup>+</sup> lung cancer patient was treated with PPV mono&#x02010;therapy, and he showed a long SD term of 26.7&#x000a0;months (Fig.&#x000a0;<xref rid="cas13189-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="cas13189-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>A case of long stable disease (<styled-content style="fixed-case">SD</styled-content>). Computed tomography findings of an <styled-content style="fixed-case">HLA</styled-content>&#x02010;A31<sup>+</sup>/A31<sup>+</sup> non&#x02010;small cell lung cancer patient (adenocarcinoma) with <styled-content style="fixed-case">PPV</styled-content> monotherapy throughout <styled-content style="fixed-case">PPV</styled-content>. (a) At diagnosis of lung cancer at stage 3a (8&#x000a0;months before <styled-content style="fixed-case">PPV</styled-content>; tumor size: 37&#x000a0;&#x000d7;&#x000a0;22&#x000a0;mm); (b) At the time of 1st vaccination of <styled-content style="fixed-case">PPV</styled-content> (tumor size: 50&#x000a0;&#x000d7;&#x000a0;35&#x000a0;mm); (c) At 3&#x000a0;months after <styled-content style="fixed-case">PPV</styled-content> (52&#x000a0;&#x000d7;&#x000a0;33&#x000a0;mm); (d) At 12&#x000a0;months after <styled-content style="fixed-case">PPV</styled-content> (53&#x000a0;&#x000d7;&#x000a0;36&#x000a0;mm); and (e) At 26&#x000a0;months after <styled-content style="fixed-case">PPV</styled-content> (64&#x000a0;&#x000d7;&#x000a0;35&#x000a0;mm). An interval of <styled-content style="fixed-case">SD</styled-content> was judged as 26.7&#x000a0;months. Red arrows indicate main tumor site.</p></caption><graphic id="nlm-graphic-7" xlink:href="CAS-108-598-g003"/></fig><p>There were no significant differences in MST between the 4 HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup>patients with increased IgG responses at the end of the first cycle and the remaining seven HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients without it. None of the cytokine levels in pre&#x02010; or post&#x02010;vaccination samples were predictive of overall survival. However, when the HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients were divided into two groups according to whether their various cytokine levels increased or decreased after PPV, those with increased IL4 or IL6 levels, but not those with increases in any other cytokines tested, showed worse prognosis than those with decreased IL4 (<italic>P&#x000a0;=&#x000a0;</italic>0.01; Fig.&#x000a0;<xref rid="cas13189-fig-0004" ref-type="fig">4</xref>a) or IL6 (<italic>P&#x000a0;=&#x000a0;</italic>0.07, Fig.&#x000a0;<xref rid="cas13189-fig-0004" ref-type="fig">4</xref>b) levels, respectively. Since the number of HLA&#x02010;A31<sup>+</sup>/A31<sup>+</sup> patients (<italic>n&#x000a0;=&#x000a0;</italic>7) was so small, it was difficult to reach any definitive conclusions in regard to these biomarkers.</p><fig fig-type="Figure" xml:lang="en" id="cas13189-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Biomarker study. When 10 <styled-content style="fixed-case">HLA</styled-content>&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients were divided into two groups according to the increase (<italic>n&#x000a0;=&#x000a0;</italic>7) or decrease (<italic>n&#x000a0;=&#x000a0;</italic>3) in each cytokine level from pre&#x02010;vaccination to the end of the first cycle, the patients with increased <styled-content style="fixed-case">IL</styled-content>4 or <styled-content style="fixed-case">IL</styled-content>6 levels showed worse prognosis than those with decreased levels in <styled-content style="fixed-case">IL</styled-content>4 (<italic>P&#x000a0;=&#x000a0;</italic>0.01; Fig.&#x000a0;<xref rid="cas13189-fig-0003" ref-type="fig">3</xref>a) or <styled-content style="fixed-case">IL</styled-content>6, respectively (<italic>P&#x000a0;=&#x000a0;</italic>0.07; Fig.&#x000a0;<xref rid="cas13189-fig-0003" ref-type="fig">3</xref>b).</p></caption><graphic id="nlm-graphic-9" xlink:href="CAS-108-598-g004"/></fig></sec></sec><sec id="cas13189-sec-0013"><title>Discussion</title><p>Although large numbers of clinical trials of peptide&#x02010;based cancer vaccine have been conducted in the past two decades, as far as we know, this is the first report of a clinical trial of peptide&#x02010;based cancer vaccines for HLA&#x02010;A11<sup>+</sup> or &#x02010;A31<sup>+</sup>cancer patients. This delay could be primarily due to the lower allele frequency (around 5%) in European, Spanish and Black populations. However, the frequencies of both alleles are relatively high in the Asian population (10% to 20%). In addition, HLA&#x02010;A11 or &#x02010;A33 shares cross&#x02010;reactive binding affinity and thus they are classified as members of the HLA&#x02010;A3 supertype. Indeed, five of nine peptides used in PPV have confirmed binding to the HLA&#x02010;A3 supertype allele, IgG responses and CTL responses.<xref rid="cas13189-bib-0010" ref-type="ref">10</xref>, <xref rid="cas13189-bib-0011" ref-type="ref">11</xref>, <xref rid="cas13189-bib-0012" ref-type="ref">12</xref> In addition, remaining four peptides were tested for the capability of CTL responses.<xref rid="cas13189-bib-0013" ref-type="ref">13</xref>, <xref rid="cas13189-bib-0014" ref-type="ref">14</xref>, <xref rid="cas13189-bib-0015" ref-type="ref">15</xref>, <xref rid="cas13189-bib-0016" ref-type="ref">16</xref> These results suggest that the shared peptides could be applicable for both HLA&#x02010;A11<sup>+</sup> and &#x02010;A31<sup>+</sup> patients. These several advantages allowed us to carry out a clinical trial of peptide&#x02010;based cancer vaccines for 18 HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> or 13 &#x02010;A31<sup>+</sup>/A31<sup>+</sup> cancer patients under the PPV over the past 7&#x000a0;years. Although we also performed the same PPV regimes for HLA&#x02010;A11 or &#x02010;A33 cancer patients who co&#x02010;expressed the other HLA&#x02010;A, including the &#x02013;A2, &#x02010;A24, or &#x02010;A3 supertype alleles, or &#x02013;A26, those results were not included in this retrospective study in order to avoid any bias in terms of the safety evaluation, immune responses, or clinical benefits, primarily because the nine peptides used in this study exhibit cross&#x02010;reactivity to the other HLA&#x02010;A molecules, including a member of the HLA&#x02010;A3 supertype.</p><p>From the viewpoint of adverse events, grade 1 or 2 injection site reaction was the primary event, observed in 68% or 19% of the patients, respectively. Grade 3 or 4 SAEs were observed in 18 cases or in one case. However, in all these cases the SAEs were concluded to be not directly associated with the PPV, but rather with the disease progression or combined therapy. These results indicated that PPV was safely conducted in HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> and &#x02010;A31<sup>+</sup>/A31<sup>+</sup> cancer patients, which is consistent with the results on PPV for the HLA&#x02010;A24<sup>+</sup> or &#x02010;A2<sup>+</sup> cancer patients reported previously.<xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref>, <xref rid="cas13189-bib-0009" ref-type="ref">9</xref>
</p><p>Successful boosting of HLA&#x02010;A11 or &#x02010;A33 restricted peptide&#x02010;specific CTL responses after the PPV was observed in only a portion of the patients tested. This may have been partly due to the deeply depressed anti&#x02010;tumor cellular responses of these patients, since CTL responses to the vaccinated peptides in pre&#x02010;vaccination PBMCs, but not CTL responses to non&#x02010;vaccinated CEF peptides reactive to virus, were undetectable in these patients (i.e., they were detectable in only one of 12 HLA&#x02010;A11 or zero of nine &#x02010;A33 patients). In contrast, peptide&#x02010;specific IgG responses were well observed in pre&#x02010;vaccination samples in all patients tested. In addition, the successful boosting was observed in nearly half of all patients tested at the end of the first or second cycles, respectively. There were several possible explanations for this discrepancy between the rate of successful CTL and IgG boosting. CD8<sup>+</sup> T cell numbers and their functions, but not the numbers and functions of CD4<sup>+</sup> T cells, are generally depressed in advanced cancer patients who become refractory to chemotherapy. The other explanation could be deletion or depressed expression of HLA&#x02010;class IA molecules on the surface of cancer cells from HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup>or &#x02010;A31<sup>+</sup>/A31<sup>+</sup>cancer patients. Cancer cells with a homogenous HLA&#x02010;class I A allele might more easily become resistant to CTL&#x02010;mediated tumor cell killing as compared to those with a heterogeneous allele, which might in turn be partly responsible for the decrease of memory/activated CTLs in circulation. Therefore, from a clinical point of view, if HLA&#x02010;A11 or &#x02010;A33 cancer patients co&#x02010;expressed the HLA&#x02010;A2 and &#x02010;A24 allele, it might be appropriate to use both peptides matched to the HLA&#x02010;A3 supertype and those matched to HLA&#x02010;A2 or &#x02010;A24. In fact, we have been doing this in PPV regimens for some time now, and have achieved high rates of successful boosting of peptide&#x02010;specific CTL responses, as reported previously.<xref rid="cas13189-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13189-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13189-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13189-bib-0006" ref-type="ref">6</xref>, <xref rid="cas13189-bib-0009" ref-type="ref">9</xref> Alternatively, the numbers of pooled peptides may have been too small to correspond to antigenic heterogeneity of tumor cells and also the diverse immune responses among cancer patients.</p><p>Clinical benefit was not the main objective of this small&#x02010;scale study for cancer patients with different histological types. Nonetheless, the clinical&#x02010;outcome data are of interest. Clinical responses consisted of four cases of stable disease and 14 of progressive disease in HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients with an MST of 332&#x000a0;days, versus seven and six cases in &#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients with an MST of 177&#x000a0;days, respectively. Notably, a longer period of SD of 26.7&#x000a0;months was observed in one HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup> lung cancer patient under PPV alone. Despite these limited data, we considered it worthwhile to analyze the ability of the various biomarkers to predict overall survival. The results indicated that an increase in IL4 or IL6 levels after PPV was an unfavorable biomarker in HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup>cancer patients. This was expected, since we previously reported that an increase of inflammatory cytokines (IL6, IL8 and others) was an unfavorable biomarker in advanced cancer patients under PPV. Although we previously reported that an increase in peptide&#x02010;specific immune responses, particularly IgG responses, was a favorable biomarker,<xref rid="cas13189-bib-0009" ref-type="ref">9</xref>, <xref rid="cas13189-bib-0017" ref-type="ref">17</xref>, <xref rid="cas13189-bib-0018" ref-type="ref">18</xref> it was not achieved in this study primarily due to the fact that successful IgG boosting was obtained in the vast majority of patients (all seven HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> and seven of nine &#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients) at the end of the second cycle. However, patients with more successful IgG boosting survived longer than those without it suggesting that peptide&#x02010;specific IgG responses could also be a favorable biomarker for the overall survival of these patients. This issue, however, will be addressed in the next clinical study with a larger number of patients.</p><p>Collectively, the results in this study suggest that, PPVs with these nine CTL epitope peptides exhibit a good safety profile and positive immunological responses in HLA&#x02010;A11<sup>+</sup> or &#x02010;A33<sup>+</sup> cancer patients. Further clinical trials are warranted.</p></sec><sec id="cas13189-sec-0015"><title>Disclosure Statement</title><p>Akira Yamada is a board member of the Green Peptide Co., Ltd. Kyogo Itoh and Akira Yamada hold stock in the Green Peptide Co., Ltd. Kyogo Itoh received research funds from Taiho Pharmaceutical Co., Ltd. No potential conflicts of interest were declared by the other authors.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="cas13189-sup-0001"><caption><p>
<bold>Table&#x000a0;S1.</bold> Adverse events during the personalized peptide vaccine.</p></caption><media xlink:href="CAS-108-598-s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13189-sup-0002"><caption><p>
<bold>Table&#x000a0;S2.</bold> Immune responses of HLA&#x02010;A11<sup>+</sup>/A11<sup>+</sup> patients after 1st and 2nd cycle of PPV.</p></caption><media xlink:href="CAS-108-598-s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13189-sup-0003"><caption><p>
<bold>Table&#x000a0;S3.</bold> Immune responses of HLA&#x02010;A33<sup>+</sup>/A33<sup>+</sup> patients after 1st and 2nd cycle of PPV. </p></caption><media xlink:href="CAS-108-598-s003.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cas13189-sec-0014"><title>Acknowledgments</title><p>This study was supported in part by the Japan Agency for Medical Research and development (AMED); by a research program of the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan; and by a grant from the Sendai Kousei Hospital.</p></ack><ref-list content-type="cited-references" id="cas13189-bibl-0001"><title>References</title><ref id="cas13189-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cas13189-cit-0001">
<string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Harada</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer</article-title>. <source>Prostate</source>
<year>2007</year>; <volume>67</volume>: <fpage>933</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">17440952</pub-id></mixed-citation></ref><ref id="cas13189-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cas13189-cit-0002">
<string-name>
<surname>Matsumoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Satoh</surname>
<given-names>T</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin</article-title>. <source>BJU Int</source>
<year>2011</year>; <volume>108</volume>: <fpage>831</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21166757</pub-id></mixed-citation></ref><ref id="cas13189-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cas13189-cit-0003">
<string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kakuma</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>H</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer</article-title>. <source>Cancer Immunol Immunother</source>
<year>2010</year>; <volume>59</volume>: <fpage>1001</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">20146063</pub-id></mixed-citation></ref><ref id="cas13189-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cas13189-cit-0004">
<string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsumoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>H</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>An open&#x02010;label, randomized phase ii trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum&#x02010;based chemotherapy</article-title>. <source>Clin Cancer Res</source>
<year>2016</year>; <volume>22</volume>: <fpage>54</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26581246</pub-id></mixed-citation></ref><ref id="cas13189-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cas13189-cit-0005">
<string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sasada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Itoh</surname>
<given-names>K</given-names>
</string-name>. <article-title>Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine</article-title>. <source>Cancer Immunol Immunother</source>
<year>2013</year>; <volume>62</volume>: <fpage>919</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">23197273</pub-id></mixed-citation></ref><ref id="cas13189-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cas13189-cit-0006">
<string-name>
<surname>Sasada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamada</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Itoh</surname>
<given-names>K</given-names>
</string-name>. <article-title>Personalized peptide vaccine for treatment of advanced cancer</article-title>. <source>Curr Med Chem</source>
<year>2014</year>; <volume>21</volume>: <fpage>2332</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">24524766</pub-id></mixed-citation></ref><ref id="cas13189-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cas13189-cit-0007">
<string-name>
<surname>Sette</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sidney</surname>
<given-names>J</given-names>
</string-name>. <article-title>Nine major HLA class I supertypes account for the vast preponderance of HLA&#x02010;A and &#x02010;B polymorphism</article-title>. <source>Immunogenetics</source>
<year>1999</year>; <volume>50</volume>: <fpage>201</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">10602880</pub-id></mixed-citation></ref><ref id="cas13189-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cas13189-cit-0008">
<string-name>
<surname>Ikeda</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kojima</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nishikawa</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Determination of HLA&#x02010;A, &#x02010;C, &#x02010;B, &#x02010;DRB1 allele and haplotype frequency in Japanese population based on family study</article-title>. <source>Tissue Antigens</source>
<year>2015</year>; <volume>85</volume>: <fpage>252</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25789826</pub-id></mixed-citation></ref><ref id="cas13189-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cas13189-cit-0009">
<string-name>
<surname>Kibe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yutani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Motoyama</surname>
<given-names>S</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer</article-title>. <source>Cancer Immunol Res</source>
<year>2014</year>; <volume>2</volume>: <fpage>1154</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">25351849</pub-id></mixed-citation></ref><ref id="cas13189-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cas13189-cit-0010">
<string-name>
<surname>Minami</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Matsueda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takedatsu</surname>
<given-names>H</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Identification of SART3&#x02010;derived peptides having the potential to induce cancer&#x02010;reactive cytotoxic T lymphocytes from prostate cancer patients with HLA&#x02010;A3 supertype alleles</article-title>. <source>Cancer Immunol Immunother</source>
<year>2007</year>; <volume>56</volume>: <fpage>689</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">16937115</pub-id></mixed-citation></ref><ref id="cas13189-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cas13189-cit-0011">
<string-name>
<surname>Naito</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Komohara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ishihara</surname>
<given-names>Y</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Identification of Lck&#x02010;derived peptides applicable to anti&#x02010;cancer vaccine for patients with human leukocyte antigen&#x02010;A3 supertype alleles</article-title>. <source>Br J Cancer</source>
<year>2007</year>; <volume>97</volume>: <fpage>1648</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">18043580</pub-id></mixed-citation></ref><ref id="cas13189-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cas13189-cit-0012">
<string-name>
<surname>Matsueda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takedatsu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>A</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Identification of peptide vaccine candidates for prostate cancer patients with HLA&#x02010;A3 supertype alleles</article-title>. <source>Clin Cancer Res</source>
<year>2005</year>; <volume>11</volume>(<issue>Pt 1</issue>): <fpage>6933</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">16203785</pub-id></mixed-citation></ref><ref id="cas13189-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cas13189-cit-0013">
<string-name>
<surname>Tamura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nishizaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>Y</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Identification of cyclophilin B&#x02010;derived peptides capable of inducing histocompatibility leukocyte antigen&#x02010;A2&#x02010;restricted and tumor&#x02010;specific cytotoxic T lymphocytes</article-title>. <source>Jpn J Cancer Res</source>
<year>2001</year>; <volume>92</volume>: <fpage>762</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11473727</pub-id></mixed-citation></ref><ref id="cas13189-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cas13189-cit-0014">
<string-name>
<surname>Imai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Harashima</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Identification of Lck&#x02010;derived peptides capable of inducing HLA&#x02010;A2&#x02010;restricted and tumor&#x02010;specific CTLs in cancer patients with distant metastases</article-title>. <source>Int J Cancer</source>
<year>2001</year>; <volume>94</volume>(<issue>2</issue>): <fpage>237</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">11668504</pub-id></mixed-citation></ref><ref id="cas13189-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cas13189-cit-0015">
<string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shichijo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tsuda</surname>
<given-names>N</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Molecular basis of T cell&#x02010;mediated recognition of pancreatic cancer cells</article-title>. <source>Cancer Res</source>
<year>2001</year>; <volume>61</volume>: <fpage>2038</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">11280764</pub-id></mixed-citation></ref><ref id="cas13189-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cas13189-cit-0016">
<string-name>
<surname>Yang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Nakao</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shichijo</surname>
<given-names>S</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA&#x02010;A24&#x02010;restricted cytotoxic T lymphocytes in cancer patients</article-title>. <source>Cancer Res</source>
<year>1999</year>; <volume>59</volume>: <fpage>4056</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">10463607</pub-id></mixed-citation></ref><ref id="cas13189-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cas13189-cit-0017">
<string-name>
<surname>Mine</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre&#x02010;existing, peptide&#x02010;specific cellular responses</article-title>. <source>Clin Cancer Res</source>
<year>2004</year>; <volume>10</volume>: <fpage>929</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">14871969</pub-id></mixed-citation></ref><ref id="cas13189-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cas13189-cit-0018">
<string-name>
<surname>Noguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mine</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Komatsu</surname>
<given-names>N</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination</article-title>. <source>Cancer Biol Ther</source>
<year>2010</year>; <volume>10</volume>: <fpage>1266</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">20935522</pub-id></mixed-citation></ref></ref-list></back></article>